cardiology-summit-2019-keynote

6 / 6

Cardiology Summit 2019 Journal of Cardiovascular Medicine and Therapeutics | Volume 3
Page 37
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
March 25-26, 2019 | Amsterdam, Netherlands
CARDIOLOGY
AND CARDIAC NURSING
3rd World Congress on
CUSTOMIZED SELECTION OF
PATIENTSWITH HIGH RISK OF
SUDDEN DEATH USING LGE-CMR –
THE STATE OF ART
The DANISH trial taught us that for a large number of patients with non-isch-
emic systolic heart failure, implanting an ICD does not decrease the mortality
and that the survival in this group of patients decreased linearly with increasing
age. Nowadays, the left ventricular ejection fraction (lower or equal with 35%)
is the key criterion of the current guidelines for implanting an ICD in primary
prevention purposes. In addition, registry data outlined that many patients (70-
80%) with DCM and out-of-hospital aborted cardiac arrest did not show a mark-
edly reduced LV-EF%. Therefore, it became clear that we need to extend the
evaluation of patients using new criteria in order to better select the patients
who are at high risk of sudden death from arrhythmic events. Late gadolinium
enhancement in CMR is a proven powerful predictor of ventricular arrhythmias
in patients with ventricular dysfunction, irrespective of ischemic or non-isch-
emic etiology. Multiple studies as well as meta-analysis, evaluating thousands
of patients, showed that the arrhythmic endpoint was reached in a significant
higher percent of patients with a positive test vs patients with a negative LGE
test. This lecture will topic the current meta-analysis and the main actual indica-
tions of performing LGE-CMR as well as the detailed explanation of the method
and its algorithms. The analysis and interpretation of data will also be covered
during this presentation. An interesting question is to be pointed out for the fur-
ther studies, aiming if patients with LGE would be ellicite for primary prevention
with ICD irrespective of their systolic function measured with the ejection frac-
tion. This question is addressing the fact that the correct selection of patients
who are at highest risk of arrhythmic events will persuade the most benefit of
ICD-therapy.
Monica Trofin, J Cardiovasc Med Ther 2019, Volume 3
Monica Trofin works as a cardiologist at the
Monza Hospital in Bucharest, Romania, which
is a part of Monza Group. She is interested in
cardiac electrophysiology and cardiac imag-
ing. She worked in Zurich, Switzerland as a
rhythmologist, taking part in studies that de-
veloped the cardiac ablation methods. Since
2015 Dr. Trofin is European certified (level 1)
in implanting cardiac devices. Focusing her
interest in cardiac magnetic resonance, she
completed fellowships in Cardiac Center
Leipzig and in CMR-Academy of Cardiac In-
stitute of Berlin, Germany. Dr. Monica Trofin
is also passionate in teaching and is highly
active in broading the quality of healthcare
in her country.
Monica Trofin
Monza Hospital Group, Romania
BIOGRAPHY